MK-677 Does NOT Slow Alzheimer's Disease Progression Despite Raising GH and IGF-1
In a randomized trial, MK-677 failed to slow Alzheimer's disease progression despite successfully elevating GH and IGF-1 — restoring the GH axis alone isn't sufficient to treat established AD.
Quick Facts
What This Study Found
MK-677 successfully increased GH/IGF-1 in AD patients but showed no clinical benefit on cognitive decline, ADAS-cog, or CDR-sb over the trial period — proving GH axis restoration alone is insufficient for treating established Alzheimer's disease.
Key Numbers
How They Did This
RCT study.
Why This Research Matters
Relevant for mk-677, neuroprotection, hormone-optimization.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding MK-677 successfully increased GH/IGF-1 in AD patients but showed no clinical benefit on cognitive decline, ADAS-cog, or CDR-sb over the trial period —
- Evidence Grade:
- strong evidence.
- Study Age:
- Published in 2008.
- Original Title:
- Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
- Published In:
- Neurology, 71(21), 1702-8 (2008)
- Authors:
- Sevigny, J J, Ryan, J M, van Dyck, C H, Peng, Y, Lines, C R, Nessly, M L
- Database ID:
- RPEP-01418
Evidence Hierarchy
Frequently Asked Questions
What was studied?
MK-677 Does NOT Slow Alzheimer's Disease Progression Despite Raising GH and IGF-1
What was found?
In a randomized trial, MK-677 failed to slow Alzheimer's disease progression despite successfully elevating GH and IGF-1 — restoring the GH axis alone isn't sufficient to treat established AD.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01418APA
Sevigny, J J; Ryan, J M; van Dyck, C H; Peng, Y; Lines, C R; Nessly, M L. (2008). Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.. Neurology, 71(21), 1702-8. https://doi.org/10.1212/01.wnl.0000335163.88054.e7
MLA
Sevigny, J J, et al. "Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.." Neurology, 2008. https://doi.org/10.1212/01.wnl.0000335163.88054.e7
RethinkPeptides
RethinkPeptides Research Database. "Growth hormone secretagogue MK-677: no clinical effect on AD..." RPEP-01418. Retrieved from https://rethinkpeptides.com/research/sevigny-2008-growth-hormone-secretagogue-mk677
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.